Therapy for High-Risk Neuroblastoma

What we are studying

The main purpose of this research study is to find out if using 2 cycles of high dose Consolidation chemotherapy, instead of 1 cycle, will decrease the chance that the neuroblastoma will grow back after therapy. This research study will also find out if adding a new anti-cancer drug to Induction therapy will decrease the number of patients who have tumor present at the end of the Induction phase of therapy. This research study will also find out if patients whose tumor does not go away with initial therapy will need a higher dose of radiation therapy.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • All Ages up to 30

Eligibility Criteria

  • Diagnosed with high risk neuroblastoma or ganglioneuroblastoma

What is involved

  • Treatment lasts about 5 months
  • Follow-Up will occur for about 10 years
  • Subjects may also participate in part 2 of the study which includes: Consolidation therapy for 2 to 5 months; Maintenance therapy for an additional 6 months

Compensation

None

Contact Information

Study Coordinator
Joy Mitchell
Email
jmitchel@wakehealth.edu
Phone
336-716-2748

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.